NasdaqGM:ADMABiotechs
Will Securities Probes Into Alleged Channel Stuffing Change ADMA Biologics' (ADMA) Narrative?
In recent weeks, ADMA Biologics has come under scrutiny as multiple law firms launched securities fraud investigations following a short-seller report alleging inflated revenue, channel stuffing, and undisclosed related-party sales tied to its plasma-derived therapies.
This wave of legal and reputational pressure raises pointed questions about the reliability of ADMA’s reported growth and the sustainability of its current business practices.
We’ll now examine how these channel-stuffing and...